Lv51
1360 积分 2024-08-09 加入
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
9小时前
待确认
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
9小时前
待确认
Comparative study of Rb1, cyclin D1 and p16 immunohistochemistry expression to distinguish lung small‐cell carcinoma and large‐cell neuroendocrine carcinoma
7天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
9天前
已完结
PT2.13.02 Multi-Cycle Low-Dose Radiotherapy Reshapes Immunochemotherapy for ES-SCLC: The SPUR Phase II Trial
9天前
已关闭
PT2.13.01 A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC
9天前
已关闭
Two patients suffering from NSCLC with a novel rearrangement mutation in RET (exon2-11del) and their response to pralsetinib as salvage treatment
11天前
已关闭
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)
11天前
已完结
Abstract CT201: HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients
12天前
已关闭
First-line versus second-line use of selpercatinib in treatment of RET fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis
12天前
已完结
皖公网安备34019202002308
